SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Chris Boylan who wrote (9031)3/9/1999 2:59:00 PM
From: opalapril  Read Replies (2) | Respond to of 17367
 
<<Do you have a reference to this? I don't remember reading this and I didn't see anything in a quick scan of the faq.>>

Sorry. The FAQ has changed. I dug down and found my post first raising this subject. Likely somewhere around it someone quoted the FAQ.

Message 5817190



To: Chris Boylan who wrote (9031)3/9/1999 6:03:00 PM
From: Cacaito  Read Replies (3) | Respond to of 17367
 
"Because of the nature of the illness and the lack of an effective treatment the FDA agreed to let XOMA shoot for an easier target
than usual."

The only thing FDA granted was to accept the PI as a PII. What we call a PII (the lancet article) was originally a PI.
Due to the good results, the lack of treatment and the good number of subjects (total 26, 25 survivors) the FDA allow Xoma to go to PIII.

But not a weaker version of a PIII.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News